DDInter1133 DDInter1628
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Mechlorethamine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Mechlorethamine {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Mechlorethamine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mechlorethamine {u} (Compound) resembles {v} (Compound) Cyclophosphamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mechlorethamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mechlorethamine {u} (Compound) resembles {v} (Compound) Cyclophosphamide
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) CHMP4A
CHMP4A {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mechlorethamine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mechlorethamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Cinoxacin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Mechlorethamine {u} (Compound) resembles {v} (Compound) Cyclophosphamide
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Mechlorethamine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) and {u} (Diease) associated with {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mechlorethamine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Mechlorethamine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ruxolitinib (Compound)
Mechlorethamine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Mechlorethamine (Compound) resembles Cyclophosphamide (Compound) and Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Mechlorethamine (Compound) resembles Cyclophosphamide (Compound) and Cyclophosphamide (Compound) downregulates CHMP4A (Gene) and CHMP4A (Gene) is downregulated by Ruxolitinib (Compound)
Mechlorethamine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Mechlorethamine (Compound) resembles Cyclophosphamide (Compound) and Cyclophosphamide (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Mechlorethamine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates RET (Gene) and hematologic cancer (Diease) associated with RET (Gene) and RET (Gene) is bound by Ruxolitinib (Compound)